<DOC>
	<DOCNO>NCT01820091</DOCNO>
	<brief_summary>To determine optimal dose schedule Fusilev prevent reduce Folotyn-related Grade 3 high oral mucositis patient Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>Phase 1 Study Fusilev® Prevent Reduce Mucositis Patients With Non-Small Cell Lung Cancer Receiving Folotyn®</brief_title>
	<detailed_description>This open-label , uncontrolled , nonrandomized , multicenter , dose-finding , single-arm , Phase 1 study primarily determine optimal dose schedule Fusilev prevent reduce Folotyn-related Grade 3 high oral mucositis .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>At least 18 year age Relapsed Refractory Non Small Cell Lung Cancer ( NSCLC ) least one line therapy Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Histologically cytologically confirm Stage III B/IV NSCLC Adequate hematological , hepatic , renal function Available first 8 week study treatment period visit clinic oral Mucositis assessment schedule day Active concurrent malignancy . If history prior malignancy exception list , patient must diseasefree least 5 year Congestive heart failure Uncontrolled hypertension Known human immunodeficiency virus ( HIV ) positive diagnosis Previous exposure Pralatrexate Pregnant breastfeed woman Major surgery within 14 day enrollment Active uncontrolled infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment Symptomatic central nervous system ( CNS ) metastases lesion treatment require . Patients receive prophylactic CNS treatment eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>